Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octafibrin phase 3 study in congenital fibrinogen deficiency
2011-002419-27Phase 3Completed
- Sponsor
- Octapharma
- Start
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Fibrinogen human in fibrinogen deficiency and congenital hypofibrinogenemia (2 arms), sponsored by Octapharma. Primary endpoint: Overall clinical assessment of haemostatic efficacy in acute bleeding. Started Apr 2014; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
fibrinogen deficiencycongenital hypofibrinogenemia
Beyond the preview
Go deeper on 2011-002419-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002419-27.